SG11201908542QA - Gip receptor activating peptide - Google Patents

Gip receptor activating peptide

Info

Publication number
SG11201908542QA
SG11201908542QA SG11201908542QA SG11201908542QA SG 11201908542Q A SG11201908542Q A SG 11201908542QA SG 11201908542Q A SG11201908542Q A SG 11201908542QA SG 11201908542Q A SG11201908542Q A SG 11201908542QA
Authority
SG
Singapore
Prior art keywords
chome
shi
muraoka
fujisawa
kanagawa
Prior art date
Application number
Inventor
Taiji Asami
Naoki Nishizawa
Ayumu Niida
Yoko Kanematsu
Mari Adachi
Shiro Takekawa
Tomoko Morimoto
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of SG11201908542QA publication Critical patent/SG11201908542QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT °Ens °nolo HE onoilooimmo oimIE (10) International Publication Number WO 2018/181864 Al (51) International Patent Classification: C07K 14/605 (2006.01) A61K 38/00 (2006.01) (21) International Application Number: PCT/JP2018/013540 (22) International Filing Date: 30 March 2018 (30.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2017-072556 31 March 2017 (31.03.2017) JP (71) Applicant: TAKEDA PHARMACEUTICAL COMPA- NY LIMITED [JP/JP]; 1-1, Doshomachi 4-chome, Chuo- ku, Osaka-shi, Osaka, 5410045 (JP). (72) Inventors: ASAMI Taiji; c/o TAKEDA PHARMA- CEUTICAL COMPANY LIMITED, 26-1,Muraoka-Hi- gashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). NISHIZAWA Naoki; c/o TAKEDA PHARMACEUTI- CAL COMPANY LIMITED, 26-1,Muraoka-Higashi 2- chome, Fujisawa-shi, Kanagawa, 2510012 (JP). NII- DA Ayumu; c/o TAKEDA PHARMACEUTICAL COM- PANY LIMITED, 26-1,Muraoka-Higashi 2-chome, Fuji- sawa-shi, Kanagawa, 2510012 (JP). KANEMATSU Yoko; c/o TAKEDA PHARMACEUTICAL COMPANY LIMIT- ED, 26-1,Muraoka-Higashi 2-chome, Fujisawa-shi, Kana- gawa, 2510012 (JP). ADACHI Mari; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1,Mu- raoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). TAKEKAWA Shiro; c/o TAKEDA PHARMA- CEUTICAL COMPANY LIMITED, 26-1,Muraoka-Hi- gashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). MORIMOTO Tomoko; c/o TAKEDA PHARMACEUTI- CAL COMPANY LIMITED, 26-1,Muraoka-Higashi 2- chome, Fujisawa-shi, Kanagawa, 2510012 (JP). (74) Agent: OHNO Seiji et al.; OHNO & PARTNERS, Marunouchi Kitaguchi Building 21F, 6-5, Martmouchi 1- chome, Chiyoda-ku, Tokyo, 1000005 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 00 pc (54) Title: GIP RECEPTOR ACTIVATING PEPTIDE 1-1 0, - -- 13 (57) : The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt © thereof and a medicament comprising the same are provided. P l -Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A 1 1-Al2-A13-A14-A15- A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P (I) 2 C wherein each symbol is as defined herein.
SG11201908542Q 2017-03-31 2018-03-30 Gip receptor activating peptide SG11201908542QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017072556 2017-03-31
PCT/JP2018/013540 WO2018181864A1 (en) 2017-03-31 2018-03-30 Gip receptor activating peptide

Publications (1)

Publication Number Publication Date
SG11201908542QA true SG11201908542QA (en) 2019-10-30

Family

ID=62089992

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908542Q SG11201908542QA (en) 2017-03-31 2018-03-30 Gip receptor activating peptide

Country Status (21)

Country Link
US (2) US10435445B2 (en)
EP (1) EP3601329A1 (en)
JP (2) JP7175912B2 (en)
KR (1) KR20190134626A (en)
CN (1) CN110709414A (en)
AR (1) AR111346A1 (en)
AU (2) AU2018246553B2 (en)
BR (1) BR112019020438A2 (en)
CA (1) CA3058361A1 (en)
CL (1) CL2019002790A1 (en)
CO (1) CO2019012271A2 (en)
EA (1) EA201992327A1 (en)
EC (1) ECSP19078239A (en)
IL (1) IL269581B1 (en)
JO (2) JOP20180028A1 (en)
MA (1) MA48998A (en)
PE (1) PE20200675A1 (en)
PH (1) PH12019502252A1 (en)
SG (1) SG11201908542QA (en)
TW (1) TWI801373B (en)
WO (1) WO2018181864A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220135638A1 (en) * 2018-09-24 2022-05-05 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
WO2020067575A1 (en) * 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
AR119471A1 (en) 2019-08-01 2021-12-22 Lilly Co Eli GIPR AGONIST COMPOUNDS
KR20220145888A (en) * 2020-03-06 2022-10-31 사노피 Peptides as selective GIP receptor agonists
WO2021193984A2 (en) * 2020-03-25 2021-09-30 Takeda Pharmaceutical Company Limited Qd dosing of gip receptor agonist peptide compounds and uses thereof
CN115916812A (en) * 2020-03-25 2023-04-04 武田药品工业株式会社 GIP receptor agonist peptide compounds and uses thereof
CA3173517A1 (en) 2020-03-31 2021-10-07 Andreas Evers Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes
AU2021312323A1 (en) 2020-07-22 2023-02-02 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
WO2022247950A1 (en) * 2021-05-28 2022-12-01 广东众生睿创生物科技有限公司 Preparation and application of polypeptide
CA3230915A1 (en) 2021-09-06 2023-03-09 Thomas Boehme New peptides as potent and selective gip receptor agonists
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
TW202330584A (en) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 Prodrugs and uses thereof
CN116891522A (en) * 2022-04-01 2023-10-17 南京知和医药科技有限公司 Long-acting glucagon-like peptide-1 derivative and preparation method and application thereof
WO2023193727A1 (en) * 2022-04-07 2023-10-12 广东众生睿创生物科技有限公司 Pharmaceutical use of polypeptide in preparation of drugs for treating and/or preventing diabetes and obesity and related diseases thereof
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04145099A (en) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Polypeptide derivative having gip-like activity and use thereof
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
SI1180121T1 (en) 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
EP1556032A1 (en) 2002-11-01 2005-07-27 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
WO2004041266A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004048363A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical Condensed ring compound
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical Thiazoline derivative and use of the same
WO2005058823A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
JP4875978B2 (en) 2004-03-15 2012-02-15 武田薬品工業株式会社 Aminophenylpropanoic acid derivatives
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (en) 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic amide derivative, and its production and use
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
CA2605778A1 (en) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2006121904A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
US8153694B2 (en) 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
WO2007013694A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Phenoxyalkanoic acid compound
WO2007018314A2 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
JP2007063225A (en) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd Imidazopyridine compound
US20090286722A1 (en) 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
WO2007028633A2 (en) 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
ZA200900154B (en) 2006-06-27 2010-03-31 Takeda Pharmaceutical Fused cyclic compounds
US8497240B2 (en) * 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
JP5399244B2 (en) 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー DPP-IV resistant GIP hybrid polypeptide with selectable properties
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
AU2007310064B2 (en) 2006-10-19 2013-03-28 Takeda Pharmaceutical Company Limited Indole compound
JPWO2008093639A1 (en) 2007-01-29 2010-05-20 武田薬品工業株式会社 Pyrazole compounds
CN101646653A (en) 2007-02-09 2010-02-10 武田药品工业株式会社 Fused ring compounds as partial agonists of ppar-gamma
WO2008136428A1 (en) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
WO2009042922A2 (en) 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
TWI474835B (en) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
EP2318433A4 (en) 2008-08-07 2012-08-08 Ipsen Pharma Sas Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
US9072703B2 (en) 2008-08-07 2015-07-07 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
EP2320923B1 (en) 2008-08-07 2014-12-24 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
CN102171244B (en) 2008-08-07 2015-05-13 益普生制药股份有限公司 Analogues of glucose-dependent insulinotropic polypeptide
JP2012512903A (en) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Amide glucagon superfamily peptide prodrug
AU2010260058B2 (en) 2009-06-16 2015-09-24 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
WO2011014680A2 (en) 2009-07-31 2011-02-03 The Board Of Trustees Of The Leland Stanford Junior University Gastric inhibitory peptide variants and their uses
CA2788304A1 (en) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
AR080592A1 (en) 2010-03-26 2012-04-18 Lilly Co Eli PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
NZ611878A (en) 2010-12-22 2015-02-27 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
EA201390941A1 (en) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн GLUCAGON ANALOGUES, EXPERIENCING ACTIVITY ON GIP RECEPTOR
JP5914641B2 (en) 2011-06-10 2016-05-11 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Glucose-dependent insulinotropic polypeptide analogs, pharmaceutical compositions and uses thereof
US20130090285A1 (en) 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
MX356641B (en) 2012-05-03 2018-06-07 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods.
ES2602486T3 (en) 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Glucagon analogs showing GIP receptor activity
SG11201408491SA (en) 2012-06-21 2015-01-29 Univ Indiana Res & Tech Corp Analogs of glucagon exhibiting gip receptor activity
AU2013366691A1 (en) 2012-12-21 2015-07-09 Sanofi Exendin-4 derivatives
SI3004155T1 (en) * 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptide compound
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
EP3065767B1 (en) 2013-11-06 2020-12-30 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
MX369770B (en) 2013-11-06 2019-11-21 Zealand Pharma As Glucagon-glp-1-gip triple agonist compounds.
TW201609799A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/GIP receptor agonists
TW201609796A (en) 2013-12-13 2016-03-16 賽諾菲公司 Non-acylated EXENDIN-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
EP3530671A3 (en) 2014-09-05 2019-11-13 University of Copenhagen Gip peptide analogues
CA2965732A1 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
WO2016077220A1 (en) 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
JP2018012644A (en) 2014-11-26 2018-01-25 武田薬品工業株式会社 Peptide compound
JOP20200119A1 (en) 2015-01-09 2017-06-16 Lilly Co Eli Gip and glp-1 co-agonist compounds
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
JP6326394B2 (en) 2015-10-09 2018-05-16 Ｋｙｂ株式会社 Mixer truck load weighing device
AU2016343775B2 (en) 2015-10-28 2021-07-29 Tufts Medical Center Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
CN116063454A (en) 2015-12-31 2023-05-05 韩美药品株式会社 glucagon/GLP-1/GIP receptor triple agonists
JP6995042B2 (en) 2016-05-24 2022-02-04 武田薬品工業株式会社 Peptide compound

Also Published As

Publication number Publication date
US20180298070A1 (en) 2018-10-18
MA48998A (en) 2020-02-05
JOP20180028A1 (en) 2019-01-30
CO2019012271A2 (en) 2020-08-21
JP2020515612A (en) 2020-05-28
ECSP19078239A (en) 2019-12-27
TW201841936A (en) 2018-12-01
PH12019502252A1 (en) 2020-06-29
KR20190134626A (en) 2019-12-04
US11174301B2 (en) 2021-11-16
CN110709414A (en) 2020-01-17
IL269581A (en) 2019-11-28
US20200140505A1 (en) 2020-05-07
PE20200675A1 (en) 2020-06-11
EP3601329A1 (en) 2020-02-05
JP2023012547A (en) 2023-01-25
CA3058361A1 (en) 2018-10-04
IL269581B1 (en) 2024-02-01
BR112019020438A2 (en) 2020-06-09
TWI801373B (en) 2023-05-11
AR111346A1 (en) 2019-07-03
EA201992327A1 (en) 2020-02-19
JP7175912B2 (en) 2022-11-21
JOP20190211A1 (en) 2019-09-15
US10435445B2 (en) 2019-10-08
WO2018181864A1 (en) 2018-10-04
CL2019002790A1 (en) 2020-05-29
AU2018246553A1 (en) 2019-10-17
AU2018246553B2 (en) 2021-11-11
AU2022200837A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
SG11201908542QA (en) Gip receptor activating peptide
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201909949XA (en) Targeted immunotolerance
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201807249YA (en) Planar-beam, light detection and ranging system
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201901251SA (en) Aminopyrimidines as alk inhibitors
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201908894SA (en) Ip6k inhibitors
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof